发明名称 Anti-HER2 antibody variants
摘要 The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
申请公布号 US8840896(B2) 申请公布日期 2014.09.23
申请号 US201012966834 申请日期 2010.12.13
申请人 Genentech, Inc. 发明人 Lowman Henry B.;Gerstner Resi B.;Carter Paul J.
分类号 C07K16/28;C07K16/46;G01N33/566 主分类号 C07K16/28
代理机构 Arnold & Porter LLP 代理人 Marschang Diane;Dreger Ginger R.;Arnold & Porter LLP
主权项 1. A method for isolating a high-affinity variant of a humanized anti-HER2 antibody, comprising: (a) producing anti-HER2 antibody variants comprising a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO: 2, wherein said light chain variable domain comprises a substitution selected from the group consisting of (a) Y49(VL)D, F53(VL)W, Y55(VL)W; and (b) D28(VL)G, N30(VL)S, T31(VL)S, R66(VL)N, Y92(VL)W; and said heavy chain variable domain comprises a substitution selected from the group consisting of (a) F100(VH)P, Y102(VH)K; and (b) F100(VH)P, Y102(VH)L, wherein numbering is according to the Kabat numbering system, or antigen-binding fragments thereof; (b) measuring binding affinities of the variants produced in (a) for HER2 extracellular domain; and (c) selecting for a high-affinity variant from step (b), when compared to the affinity of a corresponding parent anti-HER2 antibody comprising the hypervariable regions of SEQ ID NO: 1 and 2, wherein the high-affinity variant has a dissociation constant (Kd) in the nanomolar or picomolar range, and wherein the selected high-affinity variant comprises a set of substitutions selected from the group consisting of: (a) Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, Y102(VH)K; (b) Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, Y102(VH)L; and (c) D28(VL)G, N30(VL)S, T31(VL)S, R66(VL)N, Y92(VL)W, F100(VH)P, Y102(VH)K, numbered according to the Kabat numbering system.
地址 South San Francisco CA US